SMYD3 and colorectal carcinoma: Collectively, these data show that therapeutic blockade of the SMYD3/CDCP1 axis disables tumor-promoting CAF activation, restrains hepatic metastatic outgrowth, and sensitizes CRC to oxaliplatin, supporting this axis as a tractable target to improve chemotherapy response.